Staff Profile: Samarjit Patnaik

Samarjit Patnaik, Ph.D.
Samarjit Patnaik, Ph.D.

Research Scientist

Division of Pre-Clinical Innovation
Chemistry Technology (Contractor)

National Center for Advancing Translational Sciences

National Institutes of Health

Email Samarjit Patnaik

Biography

Samarjit Patnaik joined NIH in early 2009 and now works at NCATS on a chemistry team led by Juan J. Marugan, Ph.D. Patnaik focuses primarily on developing drug-like small molecule probes, mostly derived from high-throughput screening hits, to interrogate novel targets and pathways in cellular and animal disease models with a focus on rare and neglected diseases. He also devises chemical tools that facilitate target deconvolution from phenotypic assays. His work has led to the out-licensing of a class of noninhibitory chaperones for glucocerbrosidase as a prospective therapy for Gaucher disease and the initiation of a collaboration with the National Cancer Institute’s Experimental Therapeutics program for the pre-clinical development of perinucleolar compartment inhibitors as agents against cancer metastasis.

Before joining NCATS, Patnaik worked in the Oncology Medicinal Chemistry Division at GlaxoSmithKline, where his team developed the pre-clinical candidate GSK1838705A as a dual insulin growth factor-1 receptor/anaplastic lymphoma kinase inhibitor.

Patnaik received his B.Sc. in chemistry from St. Stephen’s College in Delhi, India, and a B.A. in natural sciences from Cambridge University. He received a Ph.D. in organic chemistry at Indiana University.

Research Topics

  • Lysosomal storage disorders (Gaucher, Niemann-Pick type C, mucolipidosis type IV)
  • Cancer (Eya2/Six1, perinucleolar compartment)
  • Ion channels: TRPV1 (pain), TRPML1 (lysosomal storage disorder ML4)
  • G-protein coupled receptor (neuropeptide S receptor, addiction)

Selected Publications

  1. Identification of Activators of Human Fumarate Hydratase by Quantitative High-Throughput Screening.
  2. Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
  3. Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer.
  4. Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis.
  5. Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.